Literature DB >> 8239598

Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients.

S D Nightingale1, S L Saletan, C E Swenson, A J Lawrence, D A Watson, F G Pilkiewicz, E G Silverman, S X Cal.   

Abstract

TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8239598      PMCID： PMC188084          DOI： 10.1128/AAC.37.9.1869

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment.

Authors:  N Düzgüneş; D R Ashtekar; D L Flasher; N Ghori; R J Debs; D S Friend; P R Gangadharam
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

3.  Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin.

Authors:  L E Bermudez; M Wu; L S Young
Journal:  J Infect Dis       Date:  1987-09       Impact factor: 5.226

4.  Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  S P Klemens; M H Cynamon; C E Swenson; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice.

Authors:  N Düzgüneş; V K Perumal; L Kesavalu; J A Goldstein; R J Debs; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

Authors:  J Chiu; J Nussbaum; S Bozzette; J G Tilles; L S Young; J Leedom; P N Heseltine; J A McCutchan
Journal:  Ann Intern Med       Date:  1990-09-01       Impact factor: 25.391

7.  Liposome-encapsulated-amikacin therapy of Mycobacterium avium complex infection in beige mice.

Authors:  M H Cynamon; C E Swenson; G S Palmer; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin.

Authors:  C E Swenson; K A Stewart; J L Hammett; W E Fitzsimmons; R S Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides.

Authors:  L E Bermudez; A O Yau-Young; J P Lin; J Cogger; L S Young
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

10.  Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.

Authors:  S D Nightingale; L T Byrd; P M Southern; J D Jockusch; S X Cal; B A Wynne
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226
  10 in total
  12 in total

1.  Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice.

Authors:  D C Quenelle; J K Staas; G A Winchester; E L Barrow; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

3.  Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.

Authors:  P Deol; G K Khuller; K Joshi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 4.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

Review 5.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

6.  Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation.

Authors:  M S Webb; N L Boman; D J Wiseman; D Saxon; K Sutton; K F Wong; P Logan; M J Hope
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome).

Authors:  R M Fielding; R O Lewis; L Moon-McDermott
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

8.  Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.

Authors:  I H Norville; G J Hatch; K R Bewley; D J Atkinson; K A Hamblin; J D Blanchard; S J Armstrong; J K Pitman; E Rayner; G Hall; J Vipond; T P Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

9.  Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes.

Authors:  P Lutwyche; C Cordeiro; D J Wiseman; M St-Louis; M Uh; M J Hope; M S Webb; B B Finlay
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages.

Authors:  E L Barrow; G A Winchester; J K Staas; D C Quenelle; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.